Trials / Not Yet Recruiting
Not Yet RecruitingNCT06856278
Clinical Study of NKG2D CAR-NK Combined with PD-1 Monoclonal Antibody in the Treatment of ATC
Clinical Exploratory Study of NKG2D CAR-NK Combined with PD-1 Monoclonal Antibody in the Treatment of Anaplastic Thyroid Cancer (ATC)
- Status
- Not Yet Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Zhejiang Provincial People's Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The patients with anaplastic thyroid cancer were treated with CAR-NK immune cells combined with PD-1 monoclonal antibody, and the safety and tolerability of the patients were observed and evaluated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NKG2D CAR-NK with PD-1 Antibody | Treated with CAR-NK immune cells combined with PD-1 monoclonal antibody. |
Timeline
- Start date
- 2025-02-22
- Primary completion
- 2028-12-31
- Completion
- 2029-03-01
- First posted
- 2025-03-04
- Last updated
- 2025-03-04
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06856278. Inclusion in this directory is not an endorsement.